Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies
Frontiers in Physiology · 13.05.2026 · 17
DOI: 10.3389/fphys.2026.1788973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Physiology, online erschienen am 13.05.2026. Verfasst von Dominika Stygar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cholestatic and autoimmune liver diseases, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and intrahepatic cholestasis of pregnancy (ICP), represent a heterogeneous group of conditions characterized by impaired bile flow, bile duct injury, and progressive hepatobiliary dysfunction. Oxidative stress has emerged as a critical factor linking bile acid toxicity to inflammation, fibrosis, and loss of biliary epithelium. This review synthesizes current evidence on the pathophysiological interplay between bile duct injury and oxidative stress in PSC, PBC, and ICP, with an emphasis on the role of redox imbalance in disease progression and therapeutic response. Across all three diseases, bile acid accumulation and mitochondrial dysfunction generate reactive oxygen species (ROS) that induce lipid peroxidation, DNA damage, and apoptosis in hepatocytes and cholangiocytes. Biomarkers, including malondialdehyde (MDA), 8-hydroxydeoxyguanosine (8-OHdG), and derivatives of reactive oxygen metabolites, correlate with disease severity and prognosis. Current therapeutic strategies target both bile acid metabolism and oxidative stress. Ursodeoxycholic acid (UDCA) enhances glutathione synthesis and reduces lipid peroxidation, while newer agents, such as obeticholic acid (OCA) and fibrates, act via farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) signaling to modulate bile acid homeostasis and redox balance. However, clinical outcomes remain variable, and long-term benefits are not fully established.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland.
- Bielsko-Biała Branch, Medical University of Silesia, Bielsko-Biała, Poland.
- Second Department of General Surgery, Jagiellonian University Medical College, Kraków, Poland.
- Department of Internal Medicine and Geriatrics, Jagiellonian University Medical College, Kraków, Poland.
- Department of Endoscopy, University Hospital in Kraków, Kraków, Poland.
Zitieren
APA
Stygar, D., Bogielski, B., Michalczyk, K., Skrzep-Poloczek, B., Suchocka, A., Nikiel, K., Kukla, K., Wasek, R., Staniszewski, J., Matyja, M., & Kukla, M. (2026). Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies. Frontiers in Physiology, 17. https://doi.org/10.3389/fphys.2026.1788973
Vancouver
Stygar D, Bogielski B, Michalczyk K, Skrzep-Poloczek B, Suchocka A, Nikiel K, et al. Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies. Frontiers in Physiology. 2026;17. doi:10.3389/fphys.2026.1788973
BibTeX
@article{Stygar2026,
author = {Stygar, Dominika and Bogielski, Bartosz and Michalczyk, Katarzyna and Skrzep-Poloczek, Bronisława and Suchocka, Alicja and Nikiel, Kamil and Kukla, Kazimierz and Wasek, Rafał and Staniszewski, Jakub and Matyja, Maciej and Kukla, Michał},
title = {Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies},
journal = {Frontiers in Physiology},
year = {2026},
volume = {17},
doi = {10.3389/fphys.2026.1788973}
}
EUVIMED